急性髓系白血病患者异基因骨髓移植后复发行同一供者二次移植一例

 目的　探索血缘HLA全相合骨髓造血干细胞移植（HSCT）后复发病例进行同一供者外周血造血干细胞二次移植（HSCT2）的可行性。方法　1例急性髓系白血病（M4）患者接受血缘HLA全相合供者骨髓移植后18个月复发，染色体检查提示为受者复发型。给予CY-TBI预处理后输注同一供者外周血HSCT2，同时降低预防移植物抗宿主病（GVHD）强度。结果　患者HSCT2后获得稳定植入，患者并发急性GVHD（肠道Ⅳ级，皮肤Ⅲ级），完全缓解至+8月。结论　对于血缘造血干细胞供者移植后复发的患者，HSCT2同一供者HSCT是可行的。

Second allogeneic hematopoietic stem cell transplant from one sibling donor for a patient with acute myeloid leukemia relapsed after the first transplantation

Objective To evaluate the efficacy of second allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of leukemia relapsed after first allo-HSCT from one sibling donor.Methods One patient with acute myeloid leukemia (AML-M4) underwent sibling donor bone marrow transplant (conditioning regimens was Bu/Cy) and relapsed after 18 months. The patient received the same donor's peripheral blood stem cell (PBSC) for second transplantation after receiving CY-TBI regimens,and reduced intension of prophylaxis of GVHD. Results The patient achieved stable engraftment after second HSCT. The patients suffered acute GVHD (intestinal Ⅳ and cutaneous Ⅲ) and had been complete remission to +8 months. Conclusion Second related HSCT is feasible in relapsed patient who had undergone related allo-BMT.